ClinicalTrials.gg
RecruitingNCT07853677MYORHEINUpdated Oct 2, 2026

Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis

An observational study in Rhabdomyolysis-Induced Renal Failure, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Severe rhabdomyolysis is a common medical emergency that can lead to acute kidney injury (AKI), sometimes requiring extracorporeal renal replacement therapy (ECRT). Myoglobin plays a major role among the molecules involved in nephrotoxicity. While ECRT techniques are commonly used in this situation, their actual effectiveness in eliminating myoglobin and improving renal function remains poorly established. In particular, mid-cut-off membranes, developed to better remove intermediate molecular weight molecules, could improve renal prognosis. This study aims to evaluate, using retrospective clinical data, the impact of these techniques on renal recovery.

02

Conditions studied

  • Rhabdomyolysis-Induced Renal Failure

Keywords

  • Rhabdomyolysis
  • Renal Failure
  • Extracorporeal Myoglobin
03

In context

Rhabdomyolysis

40 studies on the registry are indexed under Rhabdomyolysis; 5 are open to participants now.

This study's planned enrollment of 100 is below the median of 150 across 23 observational studies indexed under Rhabdomyolysis.

Browse Rhabdomyolysis studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patient (≥18 years) with confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥18 years).
  • Patient is hospitalized in the nephrology or medical intensive care units of the Strasbourg University Hospitals (NHC or Hautepierre) between 2015 and 2024.
  • Confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
  • Patient has not objected to the reuse of their medical data.

Exclusion criteria

Exclusion criteria:

  • Patient has objected to the reuse of their data.
  • Incomplete medical file preventing the complete analysis of the data necessary for the study.
  • Subject under guardianship, curatorship, or legal protection.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Total duration of dependence on extrarenal purification (ERP) (in days)

    Total duration of dependence on ERC (in days), defined as the number of days between initiation and discontinuation of any form of dialysis.

    Time frame: up to 15 month

07

Study locations

1 of 1 sites recruiting
  • Service de Néphrologie Dialyse Transplantation - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Nans FLORENS, MD · Contactnans.florens@chru-strasbourg.fr · 33 3 69 55 13 25
    • Nans FLORENS, MD · Principal investigator
    • Candice BARRIERE, MD · Sub investigator
    • Maxime INGWILLER, MD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Oct 2, 2026
StartActual
Apr 8, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07853677
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Apr 8, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Nans FLORENS, MD
Contact
nans.florens@chru-strasbourg.fr
33 3 69 55 13 25

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion